“By the end of 2020, export sales of the FSUE Moscow Endocrine Plant- ENDOPHARM under the jurisdiction of the Ministry of Industry and Trade of Russia, in monetary terms showed the increase by 2.7 times in relation to the level of sales in 2019. At the same time export indicators have reached the highest value over the previous 5 years. The increase in export sales in relation to 2016 amounted to 28%,"- said the head of the foreign economic activity department Oleg Rechkin.
The share of exports in the structure of total sales of ENDOPHARM pharmaceuticals also shows an increase. This indicator has doubled in comparison with the previous year.
The FSUE Moscow Endocrine Plant exports its products to 13 countries of the world. The main consumers of the Enterprise’s export products are traditionally the countries of the EAEU, the CIS, and the Middle East. Since 2019 the products of the FSUE Moscow Endocrine Plant have entered the European markets.
The active growth of the export potential of ENDOPHARM is promoted by the work on confirmation of compliance of production and the quality of products with international standards, as well as the expansion of the range of products.
In 2019, ENDOPHARM received an international GMP certificate of the European Union for the line for the production of sterile injectable drugs. In November 2020 the medical masks produced by the Enterprise received confirmation of compliance with the requirements of EU directives in the form of a CE declaration, which allowed to enter the EU markets.
In accordance with the Decision of the 58th meeting of the Interstate Council for Standardization, Metrology and Certification, state reference standards manufactured by ENDOPARM are recognized in the category of Interstate Reference Standards (IRS) and are approved for use at the territory of a number of foreign countries, which contributes to an increase in the national export of reference standards.
The development of exports in the pharmaceutical industry of the Russian Federation is one of the priority tasks of the national project "International Cooperation and Export". The FSUE Moscow Endocrine Plant predicts export growth in 2021. Negotiations are held on extension of sales markets with partners from Europe, the Middle East and Southeast Asia. The main drivers of growth in ENDOPHARM export sales in 2021 will be new drugs undergoing marketing authorization in foreign countries, including modern non-invasive forms of centrally acting analgesics.
Export Sales of the FSUE Moscow Endocrine Plant Reached the Highest Value for 5 Years
24 March 2021
Comment type is not specified in the component properties.